REGN Shares Drop 3.03% with $610M Volume Ranking 160th Amid Growth Hurdles

Regeneron Pharmaceuticals (REGN) closed August 11, 2025, down 3.03% with a trading volume of $0.61 billion, ranking 160th in market activity. Recent developments highlight the company’s Q2 2025 performance, including $3.68 billion in revenue driven by EYLEA HD and Dupixent. A key catalyst is the FDA’s approval of Dupixent for bullous pemphigoid, expanding its therapeutic reach. The firm also announced a $0.88 per share dividend and progress on share repurchases, having completed a $3 billion buyback program.

Analysts note that while Dupixent’s new indication strengthens its growth potential, near-term challenges persist for EYLEA HD, including unresolved manufacturing issues and regulatory risks. Competitive pressures and pricing dynamics for EYLEA remain critical concerns. The share repurchase program, though supportive of shareholder value, does not directly address these immediate risks. Long-term forecasts project $16.5 billion in revenue by 2028, relying on 5.1% annual growth and modest earnings expansion.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day yielded a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This underscores liquidity-driven momentum in volatile markets, where high-volume stocks amplify short-term performance. The approach benefits from diversification across sectors and capitalizes on liquidity concentration, though its success depends on timing and market conditions.